CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (UNAUDITED) - USD ($) $ in Millions		Total	Common Stock		Treasury Stock		Treasury Stock Share Repurchase Program	[3]	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Loss	Equity Attributable to Noncontrolling Interests
Beginning balance (in shares) at Dec. 31, 2020	[1]		501,900,000
Beginning balance at Dec. 31, 2020		$ 3,773	$ 5		$ (2,230)				$ 1,065	$ 5,659	$ (730)	$ 4
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest		1,621								1,623		(2)
Other comprehensive income/(loss), net of tax		63									63
Treasury stock, beginning balance (in shares) at Dec. 31, 2020	[1]				26,600,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Treasury stock acquired, shares	[1]				(3,100,000)	[2]	(1,200,000)
Share-based compensation awards	[3]	5			$ 16				(11)	0
Treasury stock acquired	[2]	(545)			(545)
Employee benefit plan contribution from Pfizer Inc.	[4]	2							2
Dividends, Common Stock		(238)								(238)
Ending balance (in shares) at Sep. 30, 2021	[1]		501,900,000
Ending balance at Sep. 30, 2021		4,681	$ 5		$ (2,759)				1,056	7,044	(667)	2
Treasury stock, ending balance (in shares) at Sep. 30, 2021	[1]				28,500,000
Beginning balance (in shares) at Jun. 30, 2021	[1]		501,900,000
Beginning balance at Jun. 30, 2021		4,352	$ 5		$ (2,568)				1,044	6,492	(623)	2
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest		552								552		0
Other comprehensive income/(loss), net of tax		(44)									(44)
Treasury stock, beginning balance (in shares) at Jun. 30, 2021	[1]				27,700,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Treasury stock acquired, shares	[1]				(1,000,000.0)	[2]	(200,000)
Share-based compensation awards	[3]	18			$ 7				11
Treasury stock acquired	[2]	(198)			(198)
Employee benefit plan contribution from Pfizer Inc.	[5]	1							1
Ending balance (in shares) at Sep. 30, 2021	[1]		501,900,000
Ending balance at Sep. 30, 2021		$ 4,681	$ 5		$ (2,759)				1,056	7,044	(667)	2
Treasury stock, ending balance (in shares) at Sep. 30, 2021	[1]				28,500,000
Beginning balance (in shares) at Dec. 31, 2021		501,891,243	501,900,000	[1]
Beginning balance at Dec. 31, 2021		$ 4,544	$ 5		$ (2,952)				1,068	7,186	(764)	1
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest		1,651								1,653		(2)
Other comprehensive income/(loss), net of tax		$ (45)									(45)
Treasury stock, beginning balance (in shares) at Dec. 31, 2021		29,317,153			29,300,000	[1]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Treasury stock acquired, shares	[1]				(6,700,000)	[2]	(600,000)
Share-based compensation awards	[3]	$ 5			$ 2				3
Treasury stock acquired	[2]	(1,189)			(1,189)
Employee benefit plan contribution from Pfizer Inc.	[4]	2							2
Dividends, Common Stock		$ (306)								(306)
Ending balance (in shares) at Sep. 30, 2022		501,891,243	501,900,000	[1]
Ending balance at Sep. 30, 2022		$ 4,662	$ 5		$ (4,139)				1,073	8,533	(809)	(1)
Treasury stock, ending balance (in shares) at Sep. 30, 2022		35,449,148			35,400,000	[1]
Beginning balance (in shares) at Jun. 30, 2022	[1]		501,900,000
Beginning balance at Jun. 30, 2022		$ 4,580	$ 5		$ (3,766)				1,059	8,004	(722)	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest		528								529		(1)
Other comprehensive income/(loss), net of tax		(87)									(87)
Treasury stock, beginning balance (in shares) at Jun. 30, 2022	[1]				33,300,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Treasury stock acquired, shares	[1]				(2,200,000)	[2]	(100,000)
Share-based compensation awards	[3]	17			$ 4				13
Treasury stock acquired	[2]	(377)			(377)
Employee benefit plan contribution from Pfizer Inc.	[5]	$ 1							1
Ending balance (in shares) at Sep. 30, 2022		501,891,243	501,900,000	[1]
Ending balance at Sep. 30, 2022		$ 4,662	$ 5		$ (4,139)				$ 1,073	$ 8,533	$ (809)	$ (1)
Treasury stock, ending balance (in shares) at Sep. 30, 2022		35,449,148			35,400,000	[1]

[1] Shares may not add due to rounding.

[2] Reflects the acquisition of treasury shares in connection with the share repurchase program. For additional information, see Note 13. Stockholders' Equity.

[3] Includes the issuance of shares of Zoetis Inc. common stock and the reacquisition of shares of treasury stock associated with exercises of employee share-based awards. Also includes the reacquisition of shares of treasury stock associated with the vesting of employee share-based awards to satisfy tax withholding requirements. For additional information, see Note 12. Share-based Payments and Note 13. Stockholders' Equity.

[4] Represents contributed capital from Pfizer Inc. associated with service credit continuation for certain Zoetis Inc. employees in Pfizer Inc.'s U.S. qualified defined benefit and U.S. retiree medical plans.

[5] Represents contributed capital from Pfizer Inc. associated with service credit continuation for certain Zoetis Inc. employees in Pfizer Inc.'s U.S. qualified defined benefit and U.S. retiree medical plans.